drugset / Trial / NCT00704392
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and highest safe doses of XL647 in combination with XL147 in adults with solid tumors. XL647 is a small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), and ErbB2. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tesevatinib | Small molecule | 50 mg | Oral |
| Subject | pilaralisib | Small molecule | 25 mg | Oral |
| Subject | pilaralisib | Small molecule | 100 mg | Oral |